Compare iShares Global Clean Energy ETF (ICLN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Pfizer Inc — how do they compare? iShares Global Clean Energy ETF trades at $18.25, while Pfizer Inc trades at $24.77 (market cap $141.06B). The key difference: Pfizer Inc pays a 6.95% dividend while iShares Global Clean Energy ETF pays none, and iShares Global Clean Energy ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| ICLN | PFE | |
|---|---|---|
52-Week High | $23.75 | $28.56 |
52-Week Low | $13.41 | $23.29 |
Market Cap | — | $141.06B |
Volume | — | 29,869,932 |
Sector | — | Health |
Enterprise Value | — | $191.72B |
Dividend Yield | — | 6.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN, the iShares Global Clean Energy ETF, is trading at $18.14, down 1.25% on the day, with a bearish technical outlook. The ETF provides exposure to 105 global renewable energy companies but lacks key valuation metrics like P/E and P/S ratios. Recent news highlights strong 2026 performance with over 25% gains, driven by AI-related power demand and global energy security concerns.
The outlook for ICLN is mixed, balancing strong sector tailwinds against policy risks. Investment opportunities include exposure to the growing clean energy transition, while risks involve US permit delays threatening $121 billion in projects and ongoing comparisons showing higher-yielding alternatives. The technical picture suggests near-term pressure with key support at $18.
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a bullish technical signal despite near-term resistance. The company maintains solid fundamentals with a P/E of 19.12, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning for a catalyst-rich 2026.
The outlook is cautiously optimistic, supported by a $28.25 analyst price target and a 38.46% buy rating. Key opportunities include dividend stability and pipeline progress, while risks involve patent cliffs and revenue normalization post-COVID. The stock presents a value proposition for income-focused investors amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
